Physician profile
Kalman Blumberg
NPI 1346234796
$397,009.64
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $60K · 2021: $92K · 2022: $87K · 2023: $51K · 2024: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $117K · Food and Beverage: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $116,642.59 |
| Food and Beverage | $504.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integrity Implants INC. | $271,072.86 | 2019-2022 | Linesider, Flarehawk |
| Integrity Implants INC. Dba Accelus | $116,433.59 | 2023-2024 | Flarehawk, Linesider |
| Nuvasive, INC. | $6,942.56 | 2019-2023 | Armada |
| Stryker Corporation | $1,694.39 | 2021-2022 | |
| Boston Scientific Corporation | $184.42 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Medtronic USA, INC. | $183.96 | 2019-2020 | |
| Aroa Biosurgery Incorporated | $161.54 | 2024 | |
| Saluda Medical Americas, INC. | $116.94 | 2023 | Evoke Scs |
| Electronic Waveform Lab, INC. | $76.69 | 2021 | |
| Depuy Synthes Sales INC. | $52.45 | 2022 | |
| Camber Spine Technologies LLC | $29.31 | 2023 | |
| Curonix LLC | $16.98 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Orthofix Medical, INC. | $15.08 | 2021 | |
| Sanara Medtech INC. | $14.94 | 2023 | Celleraterx |
| Merit Medical Systems INC | $13.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalman Blumberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.